Bimatoprost 10 mcg · intracameral implant
Antiglaucoma, Injections & Implants
Approved uses
Open-angle glaucoma or ocular hypertension
A single 10 mcg implant administered intracamerally, under aseptic conditions, once per eye
One implant per eye for life: retreatment is contraindicated because of corneal endothelial cell loss
Contraindications
- Active or suspected ocular or periocular infection
- Corneal endothelial cell dystrophy, such as Fuchs dystrophy
- Prior corneal transplantation or endothelial cell transplant, such as DSAEK
- Absent or ruptured posterior lens capsule, because the implant may migrate into the posterior segment; laser posterior capsulotomy in pseudophakic patients is not a contraindication if the intraocular lens fully covers the opening
- Hypersensitivity to bimatoprost or any other component of the product
10 mcg bimatoprost intracameral implant in a single-use applicator, in a sealed foil pouch.
Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Warnings & Precautions
- Endothelial cell loss: because of possible corneal endothelial cell loss, administration is limited to a SINGLE implant per eye, with no retreatment. Use DURYSTA with caution in patients with limited corneal endothelial cell reserve.
- Corneal adverse reactions: the presence of DURYSTA implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss, and risks are increased with multiple implants.
- Iridocorneal angle: the implant is intended to settle in the inferior angle, so use DURYSTA with caution in patients with narrow iridocorneal angles (Shaffer grade below 3) or anatomical obstruction, such as scarring, that may prohibit settling there.
- Macular edema: macular edema, including cystoid macular edema, has been reported with ophthalmic bimatoprost, including DURYSTA. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema.
- Intraocular inflammation: prostaglandin analogs, including DURYSTA, have been reported to cause intraocular inflammation; use with caution in active intraocular inflammation, such as uveitis, because it may worsen.
- Pigmentation: ophthalmic bimatoprost, including DURYSTA, has been reported to cause changes to pigmented tissues, such as increased iris pigmentation, which is likely to be permanent; inform patients before treatment, and examine regularly those who develop noticeably increased pigmentation.
- Endophthalmitis: intraocular procedures and injections, including DURYSTA, have been associated with endophthalmitis; always use proper aseptic technique and monitor patients after administration.
Common Side Effects
The most common ocular adverse reaction was conjunctival hyperemia, reported in 27% of patients. Other common ocular adverse reactions, reported in 5-10% of patients, were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, and iritis. The most common nonocular adverse reaction was headache, observed in 5% of patients.
Pregnancy: No adequate and well-controlled studies in pregnant women. Oral bimatoprost in animals produced adverse effects only at exposures far above the clinical one.
Lactation: There is no information on the presence of bimatoprost in human milk, the effects on the breastfed infant, or the effects on milk production. In animal studies, topical bimatoprost has been shown to be excreted in breast milk. Caution should be exercised when DURYSTA is administered to a nursing woman.
Safety and effectiveness of DURYSTA in pediatric patients have not been established.